(R,R)-Tramadol

(R,R)-Tramadol

SCHEMBL6543836

COc1cccc([C@@]2(O)CCCCC2CN(C)C)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1

The experimentally established mechanism targets of (R,R)-Tramadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 known ✓ P35372 11/20 1.00
▸ SLC6A2 P23975 13/20 1.00
▸ SLC6A4 P31645 13/20 1.00
▸ OPRD1 P41143 6/20 1.00
▸ OPRK1 P41145 4/20 1.00
▸ SLC22A1 O15245 3/20 1.00
▸ MEN1 O00255 2/20 1.00
▸ KMT2A Q03164 2/20 1.00
▸ CHRM2 P08172 1/20 1.00
▸ CHRM1 P11229 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(R,R)-Tramadol SCHEMBL5318670 1.00 SLC6A2 (1.00) SLC6A2SLC6A4OPRM1OPRD1OPRK1
(R,R)-Tramadol SCHEMBL11984200 1.00 SLC6A2 (1.00) SLC6A2SLC6A4OPRM1OPRD1OPRK1
(R,R)-Tramadol SCHEMBL57495 1.00 SLC6A2 (1.00) SLC6A2SLC6A4OPRM1OPRD1OPRK1
(R,R)-Tramadol SCHEMBL730723 1.00 SLC6A2 (1.00) SLC6A2SLC6A4OPRM1OPRD1OPRK1
(R,R)-Tramadol SCHEMBL7464 1.00 SLC6A2 (1.00) SLC6A2SLC6A4OPRM1OPRD1OPRK1
Tramadol SCHEMBL57496 1.00 SLC6A2 (1.00) SLC6A2SLC6A4OPRM1OPRD1OPRK1
(R,R)-Tramadol SCHEMBL14579837 1.00 SLC6A2 (1.00) SLC6A2SLC6A4OPRM1OPRD1OPRK1
(R,R)-Tramadol SCHEMBL1593740 1.00 SLC6A2 (1.00) SLC6A2SLC6A4OPRM1OPRD1OPRK1
(R,R)-Tramadol SCHEMBL3265792 1.00 SLC6A2 (1.00) SLC6A2SLC6A4OPRM1OPRD1OPRK1
(R,R)-Tramadol SCHEMBL12831358 1.00 SLC6A2 (1.00) SLC6A2SLC6A4OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1077923-B1 AN IMPROVED SYNTHESIS AND PURIFICATION OF (R*,R*)-2- (DIMETHYLAMINO) METHYL]-1-( 3-METHOXYPHENYL) CYCLOHEXANOL HYDROCHLORIDE MALLINCKRODT INC (US) 2004-01-02 — — EP claimed
EP-1210118-A2 COMPOSITION COMPRISING A TRAMADOL MATERIAL AND AN ANTICONVULSANT DRUG Ortho-McNeil Pharmaceutical, Inc. (US) 2002-06-05 — — EP claimed
US-6399829-B1 SALT FORMATION USING HYDROGEN CHLORIDE IN PRESENCE OT TOLUENE; CRYSTALLIZATION IN NITRILE SOLVENT MALLINCKRODT INC. 2002-06-04 — — US claimed
WO-2001013904-A2 COMPOSITION COMPRISING A TRAMADOL MATERIAL AND AN ANTICONVULSANT DRUG ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-03-01 — — WO claimed
US-20160039742-A1 EXTRACTION OF TRAMADOL FROM NAUCLEA LATIFOLIA SMITH UNIVERSITE JOSEPH FOURIER - GRENOBLE 1 (FR) 2016-02-11 — — US disclosed
EP-1077923-B1 AN IMPROVED SYNTHESIS AND PURIFICATION OF (R*,R*)-2- (DIMETHYLAMINO) METHYL]-1-( 3-METHOXYPHENYL) CYCLOHEXANOL HYDROCHLORIDE MALLINCKRODT INC (US) 2004-01-02 — — EP disclosed
EP-1077923-B1 AN IMPROVED SYNTHESIS AND PURIFICATION OF (R*,R*)-2- (DIMETHYLAMINO) METHYL]-1-( 3-METHOXYPHENYL) CYCLOHEXANOL HYDROCHLORIDE MALLINCKRODT INC (US) 2004-01-02 — — EP disclosed
US-6399829-B1 SALT FORMATION USING HYDROGEN CHLORIDE IN PRESENCE OT TOLUENE; CRYSTALLIZATION IN NITRILE SOLVENT MALLINCKRODT INC. 2002-06-04 — — US disclosed
US-6399829-B1 SALT FORMATION USING HYDROGEN CHLORIDE IN PRESENCE OT TOLUENE; CRYSTALLIZATION IN NITRILE SOLVENT MALLINCKRODT INC. 2002-06-04 — — US disclosed
EP-1077923-A1 AN IMPROVED SYNTHESIS AND PURIFICATION OF (R*,R*)-2- (DIMETHYLAMINO) METHYL]-1-( 3-METHOXYPHENYL) CYCLOHEXANOL HYDROCHLORIDE Mallinckrodt Inc. (US) 2001-02-28 — — EP disclosed
WO-1999061405-A1 AN IMPROVED SYNTHESIS AND PURIFICATION OF (R*,R*)-2-[ (DIMETHYLAMINO) METHYL]-1-( 3-METHOXYPHENYL) CYCLOHEXANOL HYDROCHLORIDE MALLINCKRODT INC. (US) 1999-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039742-A1 EXTRACTION OF TRAMADOL FROM NAUCLEA LATIFOLIA SMITH OPRK1, OPRD1, OPRM1 OPRM1 3/4885SLC6A2 15/4885SLC6A4 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback